Temasek Holdings’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$180M Hold
7,012,974
0.48% 40
2026
Q1
$135M Hold
7,012,974
0.44% 43
2025
Q4
$116M Buy
7,012,974
+1,657,142
+31% +$28M 0.37% 50
2025
Q3
$77.8M Hold
5,355,832
0.27% 57
2025
Q2
$74.9M Hold
5,355,832
0.29% 52
2025
Q1
$72.8M Hold
5,355,832
0.29% 47
2024
Q4
$109M Hold
5,355,832
0.43% 36
2024
Q3
$156M Sell
5,355,832
-350,513
-6% -$8.69M 0.63% 30
2024
Q2
$133M Hold
5,706,345
0.62% 32
2024
Q1
$117M Sell
5,706,345
-1,189,647
-17% -$22.4M 0.65% 28
2023
Q4
$148M Hold
6,895,992
0.83% 28
2023
Q3
$142M Hold
6,895,992
0.85% 28
2023
Q2
$204M Hold
6,895,992
1.18% 24
2023
Q1
$159M Buy
6,895,992
+379,951
+6% +$10.5M 0.94% 25
2022
Q4
$181M Buy
6,516,041
+940,000
+17% +$28M 1.06% 27
2022
Q3
$171M Buy
5,576,041
+206,554
+4% +$6.72M 1.02% 29
2022
Q2
$158M Hold
5,369,487
0.87% 28
2022
Q1
$173M Hold
5,369,487
0.73% 32
2021
Q4
$239M Hold
5,369,487
0.86% 29
2021
Q3
$271M Buy
5,369,487
+959,030
+22% +$54.1M 0.95% 24
2021
Q2
$346M Hold
4,410,457
1.16% 23
2021
Q1
$252M Hold
4,410,457
0.99% 23
2020
Q4
$369M Hold
4,410,457
1.59% 14
2020
Q3
$158M Hold
4,410,457
0.8% 23
2020
Q2
$107M Hold
4,410,457
0.64% 26
2020
Q1
$77.2M Hold
4,410,457
0.57% 24
2019
Q4
$76.8M Hold
4,410,457
0.5% 29
2019
Q3
$67.6M Hold
4,410,457
0.5% 30
2019
Q2
$91.6M Hold
4,410,457
0.65% 29
2019
Q1
$102M Hold
4,410,457
0.71% 25
2018
Q4
$91.1M Hold
4,410,457
0.63% 27
2018
Q3
$95.9M Hold
4,410,457
0.56% 35
2018
Q2
$67.3M Hold
4,410,457
0.35% 39
2018
Q1
$86.8M Hold
4,410,457
0.48% 31
2017
Q4
$69M Buy
+4,410,457
New +$79.3M 0.42% 33

Other funds holding DNLI

Temasek Holdings's DNLI Position: Q2 2026 in Review

Temasek Holdings held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 7,012,974 shares worth $180M. The position accounts for 0.48% of the portfolio, ranked #40.

Temasek Holdings first reported a position in DNLI in Q4 2017 and has held it in 35 quarters since. The position peaked at $369M in Q4 2020. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Temasek Holdings held 7,012,974 shares of Denali Therapeutics worth $180M as of Q2 2026.
  • Temasek Holdings left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up 0.48% of Temasek Holdings's portfolio in Q2 2026, its #40 holding.
  • Temasek Holdings first reported a position in Denali Therapeutics in Q4 2017 and has held it in 35 quarters since.
  • Temasek Holdings's Denali Therapeutics position peaked at $369M in Q4 2020.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Temasek Holdings's 13F filing for Q2 2026, filed 7 Aug 2026.